MaaT Pharma (EURONEXT: MAAT – the “Company”), an advanced clinical stage biotechnology company, leader in the development of Microbiome Ecosystem TherapiesTM (MET) aimed at improving the survival of cancer patients, today publishes its annual results for the year 2023 and takes stock of its activities.
To receive all financial information from MaaT Pharma in real time and for any questions, you can contact us via the following address: [email protected]